Brett S. Robinson

Statistics

Publications

Citations

H-Index

Active since

2000

Affiliations

Bristol-Myers Squibb (United States)(Current)

Pfizer (United States)

Brett S. Robinson is an author at Bristol-Myers Squibb (United States) specializing in antiretroviral therapy, antiviral pharmacology, and antiviral agents.

Publications per year

2000–2010

Publications

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

Pin‐Fang Lin, Wade Blair, Tao Wang et al. · Proceedings of the National Academy of Sciences · 2003 · 360 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Discovery of 4-Benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-gp120 Interactions

Tao Wang, Zhongxing Zhang, Owen B. Wallace et al. · Journal of Medicinal Chemistry · 2003 · 206 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents

Brett S. Robinson, Keith Riccardi, Yi-Fei Gong et al. · Antimicrobial Agents and Chemotherapy · 2000 · 196 citations

Medicine, Infectious Diseases, Pharmacology +17

In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632

Yi-Fei Gong, Brett S. Robinson, Ronald E. Rose et al. · Antimicrobial Agents and Chemotherapy · 2000 · 132 citations

Life Sciences, Infectious Diseases, Microbiology +17

Surface-specific effects of a PPARγ agonist, darglitazone, on bone in mice

M. Li, Lydia C. Pan, Hollis A. Simmons et al. · Bone · 2006 · 55 citations

Medicine, Pharmacology, Pharmacotherapy +14

1–5 of 7